Infections associated with the use of eculizumab
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Microbiology (medical)
Reference100 articles.
1. Monoclonal antibodies: magic bullets with a hefty price tag
2. Complement
3. Molecules Great and Small: The Complement System
4. Clinical Significance of Complement Deficiencies
5. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review
Cited by 118 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports;Expert Opinion on Drug Safety;2024-08-26
2. Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report;Frontiers in Pediatrics;2024-07-31
3. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data;BMC Nephrology;2024-06-19
4. Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity;Frontiers in Immunology;2024-05-10
5. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies;Transplant Infectious Disease;2024-05-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3